H.R. 4128 117th Congress
VALID Act of 2021
- Health
- Sponsor: Rep. DeGette, Diana [D-CO-1]
- Congress.gov ↗
Latest action, Jun 25, 2021: Referred to the Subcommittee on Health.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
1 cosponsor
Sponsored by Rep. DeGette, Diana [D-CO-1] (Democrat). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
0 D · 1 R
Referred to: House: Energy and Commerce Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
23ANDME, INC.
W STRATEGIES, LLC
7 reports
ABBOTT LABORATORIES
W STRATEGIES, LLC
7 reports
ADAPTIVE BIOTECHNOLOGIES
ARNOLD & PORTER KAYE SCHOLER LLP
7 reports
AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA)
RAMPY NORTHRUP LLC
7 reports
AMERICAN MEDICAL TECHNOLOGISTS
MICHAEL N. MCCARTY LAW OFFICE PLLC
7 reports
ASSOCIATION FOR MOLECULAR PATHOLOGY
IPOLICY SOLUTIONS
7 reports
ASSOCIATION OF AMERICAN MEDICAL COLLEGES
RAMPY NORTHRUP LLC
7 reports
7 reports
ILLUMINA, INC.
RAMPY NORTHRUP LLC
7 reports
LABORATORY CORPORATION OF AMERICA HOLDINGS
KELLEY DRYE & WARREN LLP
7 reports
7 reports
All 25 of 99 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| 23ANDME, INC. | W STRATEGIES, LLC | 7 | $140K | Q4 2021 | Q3 2022 | — |
| ABBOTT LABORATORIES | W STRATEGIES, LLC | 7 | $0 | Q4 2021 | Q3 2022 | yes |
| ADAPTIVE BIOTECHNOLOGIES | ARNOLD & PORTER KAYE SCHOLER LLP | 7 | $220K | Q4 2021 | Q3 2022 | yes |
| AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) | RAMPY NORTHRUP LLC | 7 | $400K | Q4 2021 | Q3 2022 | yes |
| AMERICAN MEDICAL TECHNOLOGISTS | MICHAEL N. MCCARTY LAW OFFICE PLLC | 7 | $70K | Q4 2021 | Q3 2022 | yes |
| ASSOCIATION FOR MOLECULAR PATHOLOGY | IPOLICY SOLUTIONS | 7 | $315K | Q4 2021 | Q3 2022 | yes |
| ASSOCIATION OF AMERICAN MEDICAL COLLEGES | 7 | $7.0M | Q4 2021 | Q3 2022 | yes | |
| ASSOCIATION OF AMERICAN MEDICAL COLLEGES | RAMPY NORTHRUP LLC | 7 | $0 | Q4 2021 | Q3 2022 | yes |
| BECTON DICKINSON AND COMPANY | 7 | $3.4M | Q4 2021 | Q3 2022 | yes | |
| F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES | 7 | $1.0M | Q4 2021 | Q3 2022 | yes | |
| ILLUMINA, INC. | RAMPY NORTHRUP LLC | 7 | $120K | Q4 2021 | Q3 2022 | yes |
| INFECTIOUS DISEASES SOCIETY OF AMERICA | 7 | $834K | Q4 2021 | Q3 2022 | yes | |
| LABORATORY CORPORATION OF AMERICA HOLDINGS | KELLEY DRYE & WARREN LLP | 7 | $0 | Q4 2021 | Q3 2022 | yes |
| LABORATORY CORPORATION OF AMERICA HOLDINGS | 7 | $2.4M | Q4 2021 | Q3 2022 | yes | |
| MYRIAD GENETICS, INC. | 7 | $1.5M | Q4 2021 | Q3 2022 | yes | |
| ABBOTT LABORATORIES | 6 | $6.6M | Q4 2021 | Q3 2022 | yes | |
| ADVANCED MEDICAL TECHNOLOGY ASSN | 6 | $4.0M | Q4 2021 | Q3 2022 | yes | |
| AMERICAN CLINICAL LABORATORY ASSOCIATION (ACLA) | COVINGTON & BURLING LLP | 6 | $1.4M | Q4 2021 | Q3 2022 | yes |
| CARIS LIFE SCIENCES, INC. | SPLITOAK STRATEGIES LLC | 6 | $240K | Q4 2021 | Q3 2022 | yes |
| COLLEGE OF AMERICAN PATHOLOGISTS | 6 | $689K | Q4 2021 | Q3 2022 | yes | |
| FOUNDATION MEDICINE, INC. | 6 | $650K | Q4 2021 | Q3 2022 | yes | |
| GUARDANT HEALTH | 6 | $1.3M | Q4 2021 | Q3 2022 | yes | |
| INVITAE INC. | IPOLICY SOLUTIONS | 6 | $530K | Q4 2021 | Q3 2022 | yes |
| ROCHE DIAGNOSTICS CORPORATION | HOOPER, LUNDY & BOOKMAN, P.C. | 6 | $300K | Q2 2021 | Q3 2022 | yes |
| THERMO FISHER SCIENTIFIC INC | 6 | $3.4M | Q4 2021 | Q3 2022 | yes |